Australia Allergy Diagnostics And Therapeutics Market Size & Outlook
Australia allergy diagnostics and therapeutics market, 2018-2030 (US$M)
Related Markets
Australia allergy diagnostics and therapeutics market highlights
- The Australia allergy diagnostics and therapeutics market generated a revenue of USD 346.0 million in 2023 and is expected to reach USD 598.2 million by 2030.
- The Australia market is expected to grow at a CAGR of 8.1% from 2024 to 2030.
- In terms of segment, inhaled was the largest revenue generating allergen type in 2023.
- Other Allergens is the most lucrative allergen type segment registering the fastest growth during the forecast period.
Allergy diagnostics and therapeutics market data book summary
| Market revenue in 2023 | USD 346.0 million |
| Market revenue in 2030 | USD 598.2 million |
| Growth rate | 8.1% (CAGR from 2023 to 2030) |
| Largest segment | Inhaled |
| Fastest growing segment | Other Allergens |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Inhaled, Drug, Other Allergens, Food |
| Key market players worldwide | Rohm Co Ltd, Thermo Fisher Scientific Inc, PerkinElmer, BioMerieux SA, Siemens Healthineers AG ADR, Omega Healthcare Investors Inc, Danaher Corp, Alcon Inc, AbbVie Inc, Sanofi SA, Allergy Therapeutics PLC, Pfizer Inc, Teva Pharmaceutical Industries Ltd, GSK PLC, Sun Pharmaceutical Industries, Roche Holding AG, Merck & Co Inc, Astellas Pharma Inc, Epigenomics AG |
Other key industry trends
- In terms of revenue, Australia accounted for 1.1% of the global allergy diagnostics and therapeutics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan allergy diagnostics and therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 683.8 million by 2030.
Inhaled was the largest segment with a revenue share of 51.53% in 2023. Horizon Databook has segmented the Australia allergy diagnostics and therapeutics market based on inhaled, drug, other allergens, food covering the revenue growth of each sub-segment from 2018 to 2030.
Australia’s allergy diagnostics and therapeutics market is expected to grow due to research collaborations and favorable government initiatives. Australia has one the highest prevalence of food allergies, which supports market growth. Growing cases of allergies in the region are compelling key players to focus on developing new drugs and initiating various R&D activities.
Increasing number of start-ups further boosts competition in the region. For instance, in December 2022, Aravax, a clinicalstage biotechnology company, received funding of USD 20 million in its series B funding. The funding will be used to initiate Phase 2 trials of PVX108, which is an immunotherapeutic for peanut allergy.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Allergy Diagnostics And Therapeutics Market Scope
Allergy Diagnostics And Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia allergy diagnostics and therapeutics market size, by allergen type, 2018-2030 (US$M)
Australia Allergy Diagnostics And Therapeutics Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
